Orexigen (OREX) Volatility, Shares Rise Following Positive Contrave Trial News
Tweet Send to a FriendGet Alerts OREX Hot Sheet
Up)
Trade OREX Now!
Orexigen Therapeutics, Inc. (Nasdaq: OREX) is moving higher early Wednesday, following faster than expected enrollment in its Light Study, the Contrave cardiovascular outcomes clinical trial.
Implied volatility is up 1.3 percent from Tuesday's close and at 90 percent of its trailing annual average.
Shares are about 6.5 percent higher on the session.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
Implied volatility is up 1.3 percent from Tuesday's close and at 90 percent of its trailing annual average.
Shares are about 6.5 percent higher on the session.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- J.P. Morgan (JPM) CEO Dimon Might Have Enough Votes to Stay Chairman - NY Times
- Clearwire (CLWR) Active as DISH Eyes Lightsquared Spectrum
- Will Erickson Air-Crane (EAC) Stock Crash and Burn?
Create E-mail Alert Related Categories
Insiders' Blog, Momentum Movers, OptionsRelated Entities
Options
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
